Business Context and Reporting Period
Company: Biohaven Ltd. (BHVN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Biohaven is a biopharmaceutical company focused on immunology, neuroscience, and oncology. In Q4 2025, the company initiated a strategic reprioritization to focus resources on three key clinical programs: Kv7 ion channel modulation (epilepsy), MoDE/TRAP degraders (immunology), and myostatin-activin pathway targeting (neuromuscular/metabolic diseases). Non-key programs were paused or downsized.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(738.8) | $(846.4) |
| Operating Expenses | $(745.4) | $(885.1) |
| Research & Development (R&D) | $(635.1) | $(795.9) |
| General & Administrative (G&A) | $(110.3) | $(89.2) |
| Cash, Cash Equivalents & Marketable Securities | $319.1 | $486.0 |
| Notes Payable (Fair Value) | $238.9 | $0 |
| Net Cash Used in Operating Activities | $(609.4) | $(582.5) |
Note: The company has not generated product revenue to date. The 2025 net loss improvement was primarily driven by the absence of a one-time $171.9 million non-cash expense related to the Knopp Amendment recorded in 2024.
Material Changes vs. Prior Period
- R&D Expenses: Decreased by $160.8 million (20.2%) year-over-year. This reduction is largely attributable to the $171.9 million one-time non-cash expense in 2024 for the Knopp milestone/royalty buyback. Excluding this item, program spending increased due to advancing clinical trials and milestone payments for BHV-8000 ($15.0M), BHV-1510 ($12.0M), and BHV-1530 ($10.0M).
- G&A Expenses: Increased by $21.1 million (23.6%) due to higher non-cash share-based compensation and legal fees associated with the Note Purchase Agreement.
- Liquidity: Cash and marketable securities decreased from $486.0 million in 2024 to $319.1 million in 2025. This was offset by $250.0 million in proceeds from a new Note Purchase Agreement and $188.7 million from a November 2025 public equity offering.
- Debt: In April 2025, the company entered a Note Purchase Agreement, issuing $250.0 million in senior secured notes. The liability is recorded at fair value ($238.9 million as of year-end).
Guidance, Outlook, and Risks
Management Commentary & Outlook
Management expects to continue incurring significant operating losses for the foreseeable future. The company estimates its current cash, cash equivalents, and marketable securities are sufficient to fund operations for at least 12 months from the filing date (March 2, 2026). Future funding will likely require additional equity or debt financing.
Clinical Developments & Milestones
- Troriluzole (SCA): Received a Complete Response Letter (CRL) from the FDA in November 2025 regarding the NDA for Spinocerebellar Ataxia. The company is pursuing an appeal process and Type A meeting to discuss the path forward.
- Opakalim (Epilepsy): Phase 2/3 trials in focal epilepsy are ongoing; topline results expected in H2 2026. Phase 2/3 trials for bipolar disorder and major depressive disorder failed to meet primary endpoints in 2025, and further psychiatric trials are not planned.
- BHV-1300 & BHV-1400 (Degraders): Phase 1 data showed deep lowering of target proteins. Pivotal trials for Graves' disease and IgA Nephropathy are planned for initiation in 2026.
- BHV-1510 (Oncology): Early Phase 1 data in combination with Libtayo showed encouraging anti-tumor activity (52.2% confirmed ORR across 23 evaluable participants).
Risks and Contingencies
- Regulatory Risk: The FDA CRL for troriluzole creates uncertainty regarding approval timelines and potential need for additional data.
- Debt Covenants: The Note Purchase Agreement contains covenants regarding financial statement delivery. A "going concern" qualification in future audits could trigger a default and acceleration of debt repayment.
- Litigation: A shareholder class action lawsuit was filed in July 2025 alleging securities law violations regarding disclosures on troriluzole and opakalim. The company intends to defend vigorously.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $319.1 million cash balance against the burn rate, considering the strategic reprioritization of programs.
- Troriluzole Regulatory Path: Monitor the outcome of the FDA Type A meeting and the appeal process following the November 2025 CRL.
- Debt Obligations: Review the terms of the $250 million Note Purchase Agreement, specifically the revenue interest (6.25% of troriluzole net sales) and the "True-Up Payment" obligation if the Test Date Condition is not met by December 31, 2030.
- Clinical Trial Results: Track the topline results for Opakalim in focal epilepsy (expected H2 2026) and the initiation of pivotal trials for BHV-1300 and BHV-1400 in 2026.
- Shareholder Litigation: Monitor the status of the July 2025 securities class action lawsuit.